Efficient bone marrow transduction by gene transfer with allogeneic umbilical cord blood serum and plasma: An implication for clinical trials

Human Gene Therapy

Volumn 19, Issue 7, 2008, Pages 744-752

  Moon, Noory ^a   Yang, Seung Jip ^a   Park, Bo Bae ^a   Chung, Yun Shin ^a   Lee, Jong Wook ^a   Oh, Il Hoan ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; VIRUS GLYCOPROTEIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENGRAFTMENT; EX VIVO GENE TRANSFER; EX VIVO STUDY; FLOW CYTOMETRY; GENE TRANSFER; GIBBON LEUKEMIA VIRUS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PLASMA; POLYMERASE CHAIN REACTION; RETROVIRUS; SAFETY; SCID MOUSE; SERUM; UMBILICAL CORD BLOOD; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIGENS, CD34; BONE MARROW CELLS; CATTLE; CELLS, CULTURED; CULTURE MEDIA; FETAL BLOOD; GENE TRANSFER TECHNIQUES; GLYCOPROTEINS; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA VIRUS, GIBBON APE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; PLASMA; RETROVIRIDAE; SERUM; TRANSDUCTION, GENETIC; TRANSPLANTATION, HOMOLOGOUS; VIRAL ENVELOPE PROTEINS;

BOVINAE; GIBBON APE LEUKEMIA VIRUS; MUS; VESICULAR STOMATITIS VIRUS;

EID: 47549096212     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.123     Document Type: Article

References (43)

1. Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., Marinello, E., Cattaneo, F., Vai, S., Servida, P., Miniero, R., Roncarolo, M.G., and Bordignon, C. (2002). Correction of ADA-SCID by stem cell gene therapy combined with non-myeloablative conditioning. Science 296, 2410-2413.
2. Baum, C., Dullmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D.A., and Von Kalle, C. (2003). Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101, 2099-2114.
3. Biffi, A., and Naldini, L. (2005). Gene therapy of storage disorders by retroviral and lentiviral vectors. Hum. Gene Ther. 16, 1133-1142.
4. Bogunia-Kubik, K., Natarajan, P., Madrigal, J.A., and Cohen, S.B. (2002). The effect of cord blood sera on CD69 expression. Immunol. Lett. 84, 77-80.
5. Bogunia-Kubik, K., Natarajan, P., Brown, S., Wolley, J., Alcocer, M., Fallen, P.R., Madrigal, J.A., and Cohen, S.B. (2003). Cord blood serum affects T cells ability to produce and respond to IL-2. Cytokine 22, 42-49.
6. Broxmeyer, H.E., Benninger, L., Yip-Schneider, M., and Braun, S.E. (1994). Commentary: A rapid proliferation assay for unknown co-stimulating factors in cord blood plasma possibly involved in enhancement of in vitro expansion and replating capacity of human hematopoietic stem/progenitor cells. Blood Cells 20, 492-497.
7. Candotti, F., Oakes, S.A., Johnston, J.A., Notarangelo, L.D., O'Shea, J.J., and Blaese, R.M. (1996). In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J. Exp. Med. 183, 2687-2692.
8. Cavazzana-Calvo, M., Hacein-Bey, S., De Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.L., Bousso, P., Deist, F.L., and Fischer, A. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672.
9. Cohen-Haguenauer, O., Peault, B., Bauche, C., Daniel, M.T., Casal, I., Levy, V., Dausset, J., Boiron, M., Auclair, C., Gluckman, E., and Marty, M. (2006). In vivo repopulation ability of genetically corrected bone marrow cells from Fanconi anemia patients. Proc. Natl. Acad. Sci. U.S.A. 103, 2340-2345.
10. Coroadinha, A.S., Silva, A.C., Pires, E., Coelho, A., Alves, P.M., and Carrondo, M.J. (2006). Effect of osmotic pressure on the production of retroviral vectors: Enhancement in vector stability. Biotechnol. Bioeng. 94, 322-329.
11. + cells. J. Gene Med. 3, 219-227.
12. Dick, J.E., Magli, M.C., Huszar, D., Phillips, R.A., and Bernstein, A. (1985). Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 42, 71-79.
13. Eaves, C., Miller, C., Cashman, J., Conneally, E., Petzer, A., Zandstra, P., and Eaves, A. (1997). Hematopoietic stem cells: Inferences from in vivo assays. Stem Cells 15(Suppl. 1), 1-5.
14. Eckert, H.G., Kuhlcke, K., Schilz, A.J., Lindemann, C., Basara, N., Fauser, A.A., and Baum, C. (2000). Clinical scale production of an improved retroviral vector expressing the human multidrug resistance 1 gene (MDR1). Bone Marrow Transplant. 25(Suppl. 2), S114-S117.
15. Even, M.S., Sandusky, C.B., and Barnard, N.D. (2006). Serum-free hybridoma culture: Ethical, scientific and safety considerations. Trends Biotechnol. 24, 105-108.
16. Gaspar, H.B., Parsley, K.L., Howe, S., King, D., Gilmour, K.C., Sinclair, J., Brouns, G., Schmidt, M., Von Kalle, C., Barington, T., Jakobsen, M.A., Christensen, H.O., Al Ghonaium, A., White, H.N., Smith, J.L., Levinsky, R.J., Ali, R.R., Kinnon, C., and Thrasher, A.J. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-2187.
17. Guenechea, G., Gan, O.I., Dorrell, C., and Dick, J.E. (2001). Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat. Immunol. 2, 75-82.
18. Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.P., Thrasher, A.J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., Fischer, A., Davies, E.G., Kuis, W., Leiva, L., and Cavazzana-Calvo, M. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185-1193.
19. Haviernik, P., and Bunting, K.D. (2004). Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors. Curr. Gene Ther. 4, 263-276.
20. Heim, D.A., and Dunbar, C.E. (2000). Hematopoietic stem cell gene therapy: Towards clinically significant gene transfer efficiency. Immunol. Rev. 178, 29-38.
21. Hennemann, B., Oh, I.H., Chuo, J.Y., Kalberer, C.P., Schley, P.D., Rose-John, S., Humphries, R.K., and Eaves, C.J. (2000). Efficient retrovirus-mediated gene transfer to transplantable human bone marrow cells in the absence of fibronectin. Blood 96, 2432-2439.
22. Jung, J., M.N., Ahn, J., Shin, J.C., and Oh, I.H. (2008). Accelerated expansion of bone marrow mesenchymal stem cells with higher self-renewal and osteogenic potential in allogeneic cord blood serum. Stem Cells Dev. (Submitted.)
23. Kang, E.M., and Tisdale, J.F. (2004). The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications. Curr. Hematol. Rep. 3, 274-281.
24. Kim, D.W., Chung, Y.J., Kim, T.G., Kim, Y.L., and Oh, I.H. (2004). Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. Blood 103, 1941-1948.
25. Kohn, D.B. (1996). Gene therapy for hematopoietic and immune disorders. Bone Marrow Transplant. 18(Suppl. 3), S55-S58.
26. Larochelle, A., and Dunbar, C.E. (2004). Genetic manipulation of hematopoietic stem cells. Semin. Hematol. 41, 257-271.
27. Larochelle, A., Vormoor, J., Hanenberg, H., Wang, J.C., Bhatia, M., Lapidot, T., Moritz, T., Murdoch, B., Xiao, X.L., Kato, I., Williams, D.A., and Dick, J.E. (1996). Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy. Nat. Med. 2, 1329-1337.
28. Lemischka, I.R., Raulet, D.H., and Mulligan, R.C. (1986). Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 45, 917-927.
29. Merten, O.W. (2004). State-of-the-art of the production of retroviral vectors. J. Gene Med. 6(Suppl. 1), S105-S124.
30. Mueller, P.R., and Wold, B. (1989). In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science 246, 780-786.
31. Oh, I.H., and Eaves, C.J. (2002). Overexpression of a dominant negative form of STAT3 selectively impairs hematopoietic stem cell activity. Oncogene 21, 4778-4787.
32. -) hematopoietic cells show altered expression of a subset of genes associated with early cytokine and differentiation responses of their adult counterparts. Blood 96, 4160-4168.
33. Oh, I.H., Fabry, M.E., Humphries, R.K., Pawliuk, R., Leboulch, P., Hoffman, R., Nagel, R.L., and Eaves, C. (2004). Expression of an anti-sickling β-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells. Exp. Hematol. 32, 461-469.
34. Onodera, M., Nelson, D.M., Sakiyama, Y., Candotti, F., and Blaese, R.M. (1999). Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: Improved retroviral vectors for clinical trials. Acta Haematol. 101, 89-96.
35. Petzer, A.L., Hogge, D.E., Landsdorp, P.M., Reid, D.S., and Eaves, C.J. (1996). Self-renewal of primitive human hematopoietic cells (long-term-culture- initiating cells) in vitro and their expansion in defined medium. Proc. Natl. Acad. Sci. U.S.A. 93, 1470-1474.
36. Pfeifer, G.P., Steigerwald, S.D., Mueller, P.R., Wold, B., and Riggs, A.D. (1989). Genomic sequencing and methylation analysis by ligation mediated PCR. Science 246, 810-813.
37. Sadelain, M., Lisowski, L., Samakoglu, S., Rivella, S., May, C., and Riviere, I. (2005). Progress toward the genetic treatment of the β-thalassemias. Ann. N. Y. Acad. Sci. 1054, 78-91.
38. Selvaggi, T.A., Walker, R.E., and Fleisher, T.A. (1997). Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 89, 776-779.
39. Shahdadfar, A., Fronsdal, K., Haug, T., Reinholt, F.P., and Brinchmann, J.E. (2005). In vitro expansion of human mesenchymal stem cells: Choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 23, 1357-1366.
40. Shultz, L.D., Schweitzer, P.A., Christianson, S.W., Gott, B., Schweitzer, I.B., Tennent, B., McKenna, S., Mobraaten, L., Rajan, T.V., Greiner, D.L., and Leiter, E.H. (1995). Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154, 180-191.
41. Spees, J.L., Gregory, C.A., Singh, H., Tucker, H.A., Peister, A., Lynch, P.J., Hsu, S.C., Smith, J., and Prockop, D.J. (2004). Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol. Ther. 9, 747-756.
42. Tuschong, L., Soenen, S.L., Blaese, R.M., Candotti, F., and Muul, L.M. (2002). Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum. Gene Ther. 13, 1605-1610.
43. Unkeless, J.C. (1979). Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. Exp. Med. 150, 580-596.